This combination medicine is used in situations involving certain distressing symptoms of the eye and external ear where both inflammation and bacterial presence are relevant. This medicine is commonly used for steroid-responsive inflammatory ocular conditions where there is a risk of superficial bacterial infection.

It is generally used to help address acute symptomatic episodes of the eye, including bacterial conjunctivitis, keratitis, and blepharitis, and for conditions of the external ear, such as acute otitis externa (swimmer's ear). The medication helps manage symptoms related to inflammatory or irritative states that may interfere with daily functioning, providing supportive relief that helps ease the overall symptom burden.

The combination is also applied in clinical settings marked by a heightened risk of infection following eye surgery or corneal injuries. This offers symptomatic support that helps patients cope more steadily with the challenging recovery phase and may assist with managing the risk of bacterial colonization.

“This medication is relevant for easing discomfort during acute episodes that involve pronounced irritation and the presence of susceptible bacteria.”

Therapeutic Focus: Symptom Easing The product is commonly used when symptoms intensify, and may assist with managing pronounced irritation and swelling associated with bacterial infections of the eye and ear.

Who Can and Cannot Use Dexagenta?

Eligibility to use the topical combination product Dexagenta (dexamethasone and gentamicin) is strictly defined by regulatory guidelines, focusing on absolute exclusions and specific population limitations.

Formal Contraindications (Who Must Not Use)

This medicine is contraindicated and must not be used by individuals with:

• A known hypersensitivity or allergy to dexamethasone, gentamicin, any other aminoglycoside antibiotics, or any of the inactive ingredients.
• Active infections of the treatment area caused by viruses (including Herpes Simplex Keratitis, Varicella, and Vaccinia), fungi, or mycobacteria.
• Myasthenia Gravis or similar conditions (due to the gentamicin component).
• A perforated eardrum (tympanic membrane) if using the otic (ear) preparation.

---

Population Limitations and Restrictions

Eligibility is limited for certain groups as follows:

• Pediatric Use: Safety and effectiveness have generally not been established in children below 2 years of age. Long-term use in all children should be avoided.
• Pregnancy and Lactation: Use during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus. Use is generally not recommended during breastfeeding.
• Conditional Use: Patients with Glaucoma or a family history of it require caution and monitoring of intraocular pressure. Individuals who wear soft contact lenses must remove them before application and throughout the treatment period.

Dexagenta Interactions with other medicines and products

Interactions documented in regulatory sources for Dexagenta (Dexamethasone and Gentamicin) relate to the potential for systemic exposure of its components, primarily involving additive toxicity and metabolic changes.

Documented Pharmacodynamic and Contraindications

Co-administration with curare-type muscle relaxants is contraindicated due to the risk of neuromuscular blockade and potential respiratory paralysis associated with the Gentamicin component. The label notes that combining Gentamicin with other systemic nephrotoxic agents (e.g., cisplatin) or potent diuretics (e.g., furosemide) may enhance the risk of ototoxicity (hearing or balance impairment) and nephrotoxicity.

Pharmacokinetic and Exposure-Altering Interactions

Interactions involving the Dexamethasone component are documented with strong CYP3A4 inhibitors (e.g., antifungals like ketoconazole), which can increase plasma concentrations of Dexamethasone. Conversely, strong CYP3A4 inducers (e.g., rifampicin, phenytoin) may decrease plasma concentrations. Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) increases the risk of gastrointestinal ulcers and bleeding.

Population and Substance Notes

The risk of systemic toxicities, particularly ototoxicity from Gentamicin, is documented as enhanced in patients with hepatic or renal impairment and more likely in the elderly. The official documents also note that alcohol use may increase susceptibility to stomach irritation when combined with the Dexamethasone component.

Glucocorticoid Receptor Activation and Genomic Suppression

The anti-inflammatory action initiates when Dexamethasone acts as an agonist on the Intracellular Glucocorticoid Receptor (GR), leading to a complex that primarily suppresses pro-inflammatory genes by inhibiting transcription factors like NF-κB. This genomic modulation limits the host's production of local chemical mediators (cytokines and prostaglandins), dampening the signaling cascade that modulates cellular infiltration and microvascular permeability.

Irreversible Arrest of Bacterial Protein Synthesis

The anti-infective component, Gentamicin, exerts a bactericidal effect by binding irreversibly to the 30S ribosomal subunit of susceptible bacteria. This targeted molecular inhibition forces widespread mistranslation of the mRNA template, resulting in the rapid manufacture of toxic, non-functional proteins that ultimately destroy the integrity of the bacterial cell, resulting in bactericidal activity.

Functional Synergy and Mechanistic Constraints

The components create a functional synergy where the antibiotic's mechanism results in pathogen cell death while the corticosteroid's genomic suppression modulates the local inflammatory cascade. However, the Gentamicin mechanism is subject to environmental constraints, as its required active transport system is significantly impaired in anaerobic or highly acidic microenvironments, limiting the compound's mechanistic activity in severe tissue states.

How to Use Dexagenta

Dexagenta, a fixed-dose combination product containing Dexamethasone and Gentamicin, is intended for topical administration only, with approved usage limited to the ocular (eye) and auricular (external ear canal) routes. The medicine is supplied as a sterile solution/suspension (drops) or an ointment.

---

Official Administration Guidelines

Administration follows a short-term, high-frequency protocol that must be tapered.

Usage Aspect	Official Instructions	Administration Constraint
Route & Form	Topical Ocular Drops/Ointment; Topical Auricular Drops.	Shaking the suspension well is required before use.
Dosing Schedule	Ocular: 1 to 2 drops or a 1 cm ointment strip. Auricular: 2 to 4 drops.	The dropper or tube tip must not touch any surface during application.
Frequency	Highly variable: initial dosing may be as frequent as every 1 to 2 hours; reduced to 3 to 6 times daily for maintenance.	Frequency must be gradually decreased as the condition improves.
Duration Limit	The full course of treatment should typically not exceed 14 days and must not exceed 3 weeks.	This medicine is for short-term use only.

---

Population and Procedural Rules

The medicine's use is subject to specific procedural and population rules. For pediatric patients, topical dosing is often similar to the adult regimen, although official labeling generally does not recommend its use in children under 2 years of age.

Before administering the product in the ear, the integrity of the tympanic membrane (eardrum) must be assessed. If the medicine is a suspension, the contents must be thoroughly mixed prior to each application. Following the mandated short duration, treatment must be discontinued entirely, with tapering required before cessation.

Research evidence / Overview of Studies for Dexagenta

Evidence for use in Steroid-Responsive Ocular Conditions

This section will summarize the structure of clinical research in studies exploring localized eye inflammation where a risk of bacterial infection exists, detailing the primary outcomes measured in short-term comparative trials and systematic reviews.

The research base for this preparation, and similar combination products, has primarily utilized short-term Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity and often involved populations such as adult patients recovering after cataract surgery or those with inflammatory conditions like blepharitis. Researchers in these settings monitored outcomes linked to inflammatory or irritative states, focusing on objective measures such as changes in flare and cell counts inside the eye, which are physical signs of inflammation. Studies also monitored visual acuity.

Evidence for use in Localized External Ear Infections

This block will describe the existing evidence, primarily systematic reviews and randomized controlled trials, that evaluated the combination for external ear infections, and will outline the key measurements researchers used to assess the resolution of symptoms and infection.

The evidence base for this type of preparation was evaluated in conditions like acute otitis externa (AOE) and relies heavily on systematic reviews and meta-analyses that consolidate findings from multiple RCTs. These studies explored outcomes related to physical discomfort and the resolution of infection, such as the resolution of symptoms and the cessation of ear discharge. The studies monitored these outcomes over defined short-term intervals, and included both adult and pediatric subjects.

Long-Term Studies and Follow-up Durations

Clinical research exploring short-term symptom changes for both the eye and ear indications typically involves short follow-up durations, primarily ranging from 7 to 21 days. The research provides context but not individual predictions about long-term use or the durability of the observed short-term effects. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the patterns of symptom recurrence or the need for repeated treatment.

What is Still Uncertain About the Research Base

A key uncertainty in the evidence base stems from comparative evidence being limited. Many pivotal studies relied on comparisons to similar steroid-antibiotic combinations rather than comparing Gentamicin/Dexamethasone directly to monotherapy or placebo in every approved setting. Additionally, evidence quality varies across studies, especially for specific otic conditions where the certainty of evidence for the added value of the steroid component remains low. The studies contribute to the broader evidence landscape; however, comparative evidence remains lacking in some areas.

Key Studies & References

1. Systematic review of topical antimicrobial therapy for acute otitis externa
2. Short-term use of dexamethasone/netilmicin fixed combination in control and treatment of post-surgical ocular inflammation following uncomplicated cataract surgery

Common questions about Dexagenta (FAQ)

Q: Can I wear my soft contact lenses while I'm on this treatment?

Official product information indicates that soft contact lenses must be removed before application. Lenses should generally remain removed for the entire treatment period, as this is a common guideline for ophthalmic medications.

Q: Does the medicine need to be shaken before I put it in my ear or eye?

This depends on the form of the medicine. If the medicine is supplied as a sterile suspension (a type of drop), official guidance states it should be shaken well before use. This mixing requirement applies only to the suspension form, not the solution or ointment.

Q: What happens if I forget a dose of the eye drops?

Regulatory information suggests that if a dose is missed, it can be applied as soon as it is remembered. However, if the time is close to the next scheduled dose, the product label indicates the missed dose should be skipped to return to the regular schedule.

Q: Why is there an age restriction for using this medicine in young children?

Official product information notes that safety and effectiveness for this medicine have generally not been established for children under 2 years of age. Therefore, the medicine is typically not recommended for this age group.

Q: How long does it typically take for the symptoms of an ear infection to start improving?

General patient information for acute ear infections suggests that symptoms often begin to show signs of improvement within 48 to 72 hours after starting treatment. This timeline is based on typical recovery expectations for localized infections.

Q: Can I drive a car after I put the ointment in my eye?

Official product information notes that using the medication may cause temporary blurred vision. Because of this potential adverse reaction, activities like driving or operating machinery should be avoided until vision is completely clear.

Q: If I have to use another eye drop at the same time, how far apart should I space the applications?

General patient information for topical eye products suggests separating applications to allow each dose to take effect. To help ensure the medicine is not washed out, other eye drops are typically applied at least five minutes apart from the Dexagenta application.

Storage and Disposal Requirements for Dexagenta

Official labeling for Dexamethasone/Gentamicin combination products mandates specific conditions to maintain stability and ensure safe handling.

---

Storage Conditions

• Temperature: Store at Controlled Room Temperature, specifically 20°C to 25°C (68°F to 77°F).
• Protection: The medicine must be protected from light and must not be frozen.
• Container: Keep the product in its original, tightly closed container.
• Stability: Multi-dose solutions often must be discarded within 28 days of first opening.
• Child Safety: Keep out of the sight and reach of children at all times.

---

Disposal Instructions

Unused or expired product must not be disposed of in household trash or down the sink (via wastewater). It should be taken to a pharmaceutical waste collection program or a local pharmacy for proper disposal, following all local and national regulations.